In short
Clinical trials are investigating VOTOPLAM in people with Huntington’s disease. The study is looking at long-term safety and whether the treatment lowers a blood marker linked to the disease. It is a Phase 2 trial in adult participants.
Key points
- Clinical trials of VOTOPLAM are being done in people with Huntington’s disease. The main study provided is a Phase 2 extension trial, which means it follows earlier research and looks at longer-term results. Researchers are checking safety, including side effects, lab tests, vital signs, physical exams, and suicide risk screening. The trial is also measuring blood total huntingtin (tHTT) levels over time to see whether the treatment changes this disease-related marker. The study is authorised and plans to enroll 250 participants.
Trial overview
The available clinical trial is a Phase 2b, double-blind, randomized extension study of VOTOPLAM in people with Huntington’s disease. The study is designed to evaluate long-term safety and efficacy, with a focus on blood total huntingtin (tHTT) levels.
Study design and phase
This is an interventional study, which means participants receive a study treatment and researchers observe the results. It is described as double-blind, meaning participants and study staff do not know which treatment is being given during the blinded part of the study.
The trial is listed as Phase 2 and also described in the title as Phase 2b, which is a later part of Phase 2 research. Phase 2 studies are usually done to look more closely at safety and early signs that a treatment may help.
Who can participate
The trial is for participants with Huntington’s disease. The source data do not give more details about age limits, disease stage, or other entry rules, so those cannot be confirmed here.
What is measured in the study
The main safety measure is the safety profile of VOTOPLAM, which is checked through treatment-emergent adverse events (new or worsening health problems during the study), laboratory abnormalities, vital signs, physical examinations, and the C-SSRS. The C-SSRS is a screening tool used to check for suicidal thoughts or behavior.
The study also measures blood total huntingtin (tHTT) levels over time. This is a pharmacodynamic measure, meaning it helps show whether the treatment is changing a disease-related marker in the body.
The brief summary says the study aims to evaluate long-term safety and the reduction of blood tHTT levels, which is the main sign of possible efficacy in the source data.
Trial status and size
The trial status is listed as Authorised, meaning it has been approved to proceed. The planned enrollment is 250 participants.
The interventions listed include VOTOPLAM tablets and placebo tablets, which shows that some participants may receive an inactive look-alike treatment for comparison. The source data do not provide the full treatment schedule or the exact randomization groups, so those details are not described here.